In a report issued on January 29, Echelon Wealth Partners also initiated coverage with a Buy rating on the stock with a C$15.00 price target. Long Term Growth Rate: Net Profit EPS DPS Net Profit EPS DPS Consensus Estimate 1m Change 3m Change Analyst Consensus. Antibe Therapeutics (ATE) ATE, 1M. Already at $0.40/share, almost double the price since I wrote this. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. 326 E 8th St #105, Sioux Falls, SD 57103. The agreement provides Nuance with exclusive rights to commercialize otenaproxesul, Antibe’s chronic pain drug, in China, Hong Kong, Macau, and Taiwan. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Targeting blockbuster opportunities for safer, non-addictive therapeutics for pain and inflammation. 2 Wall Street analysts have set twelve-month price targets for Antibe Therapeutics in the last year. Antibe Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.64, a 248.9% upside from current levels. This price target is based on 2 analysts offering 12 month price targets for Antibe Therapeutics in the last 3 months. The average price target represents a 56.88% upside from the last price of C$4.94. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. Find the latest ANTIBE THERAPEUTICS INC (ATE.TO) stock quote, history, news and other vital information to help you with your stock trading and investing. This is down from the average last month, which was C$18.22. The stock will rally higher to around the existing price just after last years Phase 2b successful results. If you are looking for stocks with good return, Antibe Therapeutics Inc can be a profitable investment option. Giddy Up! The analyst’s $1.40 target price represents a one-year projected return on investment of 312 per cent at the time of publication. Earnings reports or recent company news can cause the stock price to drop. Learn more. Maxim Group restated a “buy” rating on shares of Antibe Therapeutics in … The firm currently has a buy rating on the stock. Their average twelve-month price target is $7.95, predicting that the stock has a possible upside of 104.27%. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc. The company’s shares closed last Monday at $3.10. Latest Analyst Research & Price Targets for Antibe Therapeutics Inc (ATE-T). Could hit the second and continue the up move if the +ve divergence stays. Latest Share Price and Events Stable Share Price : ATE is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week. You'll be provided with Antibe Therapeutics Inc. overall consensus estimations for strong buy, strong sell or hold, based on analyst 12-Month price targets. Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. The next few weeks could decide your wealth in 2021. Learn about financial terms, types of investments, trading strategies and more. Echelon Wealth Partners has the lowest price target set, forecasting a price of $1.40 for Antibe Therapeutics in the next year. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Comment? Re: Antibe Therapeutics: cybercanuck: 2/9/21 12:53 PM: That Phase 3 looks so , so, so , ... trying to find the right word assured ? The company has a 50 day simple moving average of C$2.37 and a two-hundred day simple moving average of C$0.88. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. On average, they expect Antibe Therapeutics' share price to reach C$7.75 in the next twelve months. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The average price target represents a 117.21% upside from the last price of $3.66. Finance PhD: Move Your Money Before April 30th. $13.50 High $16.00 Mar '20 Jun '20 Sep '20 Dec '20 Mar '21 Mar '22 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 Based on an average daily trading volume, of 49,500 shares, the days-to-cover ratio is presently 3.2 […] MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Shares in Antibe Therapeutics Inc are currently priced at C$4.06. We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Learn everything you need to know about successful options trading with this three-part video course. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Antibe Therapeutics (OTCMKTS:ATBPF) had its price objective reduced by Canaccord Genuity from $16.50 to $14.50 in a research report report published on Thursday, The Fly reports. Antibe Therapeutics Stock Forecast, ATBPF stock price prediction. Antibe Therapeutics Inc. (ATE-X) August 1, 2019 Market cap of $69 million. The current consensus among 3 investment analysts is to buy stock in Antibe Therapeutics. Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside. You can opt out at any time. Fundamental company data provided by Zacks Investment Research. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Echelon Wealth Partners analyst Stefan Quenneville reiterated a Buy rating on Antibe Therapeutics (ATBPF – Research Report) on February 25 and set a price target of C$16.00.The company’s shares closed last Wednesday at $3.93. Price target in 14 days: 4.413 USD. PriceTargets.com does not provide financial advice and does not issue recommendations or offers to buy stock or External Link (TipRanks). NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES. Created with Highcharts 9.0.0 — Past 12 Months — 12-Month Forecast — Price Low $10.00 AVG. 2. Is Antibe Therapeutics Inc. worth watching? Stock analysis for Antibe Therapeutics Inc (ATE:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. They are testing it on over 350 patients in 35 different facilities. Canaccord Genuity lowered their target price on Antibe Therapeutics from $16.50 to $14.50 and set a “buy” rating for the company in a research note on Thursday, February 25th. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy.". Analysts covering Medicenna Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.336 for the next financial year. Looking for new stock ideas? The most optimistic Antibe Therapeutics analyst has a price target of CA$3.00 per share, while the most pessimistic values it at CA$1.00. According to TipRanks.com, McCarthy is a top 100 analyst with an average return of 57.5% and a 63.1% success rate. View the latest price targets for ATBPF. Skip to main content. Antibe Therapeutics (OTCMKTS:ATBPF) had its price objective lifted by Canaccord Genuity from $15.00 to $16.50 in a research report released on Wednesday, The Fly reports. It’s designed to give you a head start in learning the basics of various TA tools and techniques. Identify stocks that meet your criteria using seven unique stock screeners. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). They are only one of five analysts who have price targets and recommendations on Antibe Therapeutics. Find the latest ANTIBE THERAPEUTICS INC (ATBPF) stock quote, history, news and other vital information to help you with your stock trading and investing. The average target price of 5 analysts is $16.56. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. At the current price of C$0.105, shares in iCo Therapeutics Inc are trading at 84.13% against their 200 The Company is focused on pain, inflammation and regenerative medicine. PriceTargets.com provides comprehensive coverage of stock ratings, including equities research analysts’ upgrades, downgrades, new coverage and price target Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). So we wouldn't be … Yield 0% (Analysts’ price target is $1.45) Show full opinion Hide full opinion. Ratings Network’s free daily newsletter. We would probably assign less value to the analyst forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. Get the latest stock price for Antibe Therapeutics Inc. (ATE), plus the latest news, recent trades, charting, insider activity, and analyst ratings. Antibe Therapeutics (ATBPF) In a report issued on January 19, Jason McCarthy from Maxim Group reiterated a Buy rating on Antibe Therapeutics, with a price target of C$10.00. The high price target for ATBPF is $14.50 and the low price target for ATBPF is $1.40. How has Antibe Therapeutics's share price performed over time and what events caused price changes? In the last year. Based on 3 analysts offering 12-month price targets for Antibe Therapeutics Inc. in the last 6 months. A " 5 star" analyst has a target of $26.23. changes. Find the latest ANTIBE THERAPEUTICS INC (ATE.TO) stock quote, history, news and other vital information to help you with your stock trading and investing. View live ANTIBE THERAPEUTICS INC chart to track its stock's price action. Its technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved and patented medicine. You can opt out at any time. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Antibe Therapeutics (TSE:ATE) had its price target cut by research analysts at Canaccord Genuity from C$16.50 to C$14.50 in a research note issued to … The Stock That Is Disrupting A Billion Dollar Industry. Why is Antibe Therapeutics Inc. stock dropping? Sign-up to receive the latest news and ratings for ATBPF and its competitors with Analyst Antibe Therapeutics Inc develops safer, non-addictive medicines for pain and inflammation. © American Consumer News, LLC dba MarketBeat® 2010-2021. View the latest analyst ratings for ATBPF. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Antibe Therapeutics (TSE:ATE) had its price target cut by research analysts at Canaccord Genuity from C$16.50 to C$14.50 in a research note issued to … Stable Share Price: ATE is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week. View the latest ratings for ATBPF. Analysts covering Antibe Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.75 for the next financial year. Antibe Therapeutics (ATBPF) In a report issued on February 12, Stefan Quenneville from Echelon Wealth Partners reiterated a Buy rating on Antibe Therapeutics, with a price target of C$16.00. See today’s analyst top recommended stocks >> Their average twelve-month price target is $7.95, suggesting a possible upside of 117.2%. When you invest in penny stocks you need to realize that your job is finding the unicorn, mainly dealing with two types of companies: Early startups: Even big players like Amazon once started out as small companies with IPO prices far below their current value (<2$ in 1997). Move your mouse over past months for details. ***** Happy New Year! Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. Canaccord Genuity lowered their target price on Antibe Therapeutics from $16.50 to $14.50 and set a “buy” rating for the company in a research note on Thursday, February 25th. For those looking for a triple return pre-phase 2b Part B results I recommend you buy shares of ATE.V before the August 2019 data read out. Antibe Therapeutics Inc quote is equal to 3.876 USD at 2021-04-10. Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. The company's drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. Separately, Maxim Group reissued a buy rating on shares of Antibe Therapeutics in a research report on Tuesday, February […] Antibe Therapeutics Inc. (OTCMKTS:ATBPF) was the target of a significant decline in short interest in March. Canaccord Genuity has the highest price target set, predicting ATBPF will reach $14.50 in the next twelve months. All rights reserved. Canaccord Genuity has the highest price target set, predicting ATBPF will reach $14.50 in the next twelve months. Antibe is developing drugs for pain and inflammation that have improved side-effect profiles based on the company’s platform of hydrogen sulfide-releasing (H2S) analogs. How has Antibe Therapeutics's share price performed over time and what events caused price changes? This price target is based on 3 analysts offering 12 month price targets for Antibe Therapeutics in the last 3 months. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Our Antibe Therapeutics Inc. consensus estimates page is based on consensus analyst forecast, covering public companies earnings per share and revenue. 4 About The Author / Nick Waddell Their average twelve-month price target is C$7.75, predicting that the stock has a possible upside of 58.81%. Based on our forecasts, a long-term increase is expected, the "ATBPF" stock price prognosis for 2026-03-31 is 13.891 USD. The company's drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. A " 5 star" analyst has a target of $26.23. Real-time Price Updates for Antibe Therapeutics Inc (ATE-T). Antibe Therapeutics currently has 3 buy ratings from Wall Street analysts. The clock just starting ticking on the biggest financial event in 20 years. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Start Your Risk-Free Trial Subscription Here, Aphria Catches COVID-19, Revenue Down On Lockdowns, 3 Digital Media Stocks Setting Up For Further Gains, McDonald’s Doubles Down on Digital, Delivery, and Drive-Thru, Sleeping Giant Cisco Stock is Reawakening For a Huge Breakout, 3 Growth Stocks Displaying Market Leadership, 7 Bellwether Stocks Signaling a Return to Normal, 7 Electric Vehicle (EV) Stocks That Are Ready to Rebound, 7 Sports Betting Stocks That Will Shine Beyond March Madness, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, Receive Analysts' Upgrades and Downgrades Daily. Telesta Therapeutics Inc. is a human therapeutics company. According to TipRanks.com, Quenneville is ranked #3920 out of 7343 analysts. 2 stock analysts on Stockchase covered Antibe Therapeutics Inc. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. According to TipRanks.com, Quenneville is ranked #3920 out of 7343 analysts. View which stocks are hot on social media with MarketBeat's trending stocks report. Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. Receive a free world-class investing education from MarketBeat. Antibe Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.64, a 248.9% upside from current levels. Based on 3 analysts offering 12-month price targets for Antibe Therapeutics Inc. in the last 6 months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Their forecasts range from C$1.00 to C$14.50. Canaccord initiated coverage on Antibe Therapeutics with a speculative buy recommendation and a C$1.50 12 month price target, or a 261% upside. Currently, the analyst consensus on Antibe Therapeutics is a Strong Buy with an average price target of $13.24, which is a 204.4% upside from current levels. 3 Wall Street analysts have issued ratings and price targets for Antibe Therapeutics in the last 12 months. Latest Share Price and Events. Antibe Therapeutics' physical mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. 2 Wall Street analysts have set twelve-month price targets for Antibe Therapeutics in the last year. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. Our Accessibility Statement | Terms of Service | Do Not Sell My Information. In a report issued on February 12, Echelon Wealth Partners also reiterated a Buy rating on the stock with a C$16.00 price target. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Long. Get New Antibe Therapeutics Analyst Ratings Delivered To Your Inbox. The following Wall Street analysts have issued reports on Antibe Therapeutics in the last year: Canaccord Genuity, Echelon Wealth Partners, and Maxim Group. At that level they are trading at 0.119% discount to the analyst consensus target price of 0.00. Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. The most optimistic Antibe Therapeutics analyst has a price target of CA$3.00 per share, while the most pessimistic values it at CA$1.00. Trend lines and crossovers also support an up move. Quenneville has an average return of 9.3% when recommending Antibe Therapeutics.. 1) Get your target right: find the unicorn among dying companies. Antibe Therapeutics has a 12 month low of C$0.70 and a 12 month high of C$8.90. The company's listed phone number is 416-922-3460 and its investor relations email address is [email protected] The official website for Antibe Therapeutics is www.antibethera.com. Re: Antibe Therapeutics: cneman66: 2/9/21 11:39 AM: wow - r u the % star analyst sir? All rights reserved. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Strong Sell Sell Hold Buy Strong Buy. Price Target: (below Price) 31st Dec 2021 31st Dec 2022 Est. Their average twelve-month price target is C$7.75, predicting that the stock has a possible upside of 66.67%. At that level they are trading at 0.288% discount to the analyst consensus target price of 0.00. This suggests a … TORONTO, CANADA — (March 3, 2021) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions, today announced its participation in the following investor conferences in March: H.C. Wainwright … Note on Tuesday, February 2nd Therapeutics in the last price of 0.00 bleeding... Tipranks.Com, McCarthy is a biotechnology company exploiting groundbreaking advances in inflammation science safer. A non-steroid anti-inflammatory drug in the last 6 months the up move if the +ve divergence.. Analysts covering Antibe Therapeutics Inc ( ATE-T ) of 5 analysts is to buy stock or sell any.! Clean-Energy Profit-Stocks Liberty Through Wealth e-newsletter and a 63.1 % success rate of. Issued ratings and price targets for Antibe Therapeutics, Inc. is a biotechnology company exploiting groundbreaking advances in inflammation.! Charting, Tear Sheets, Press, price Performance & more inflammation and regenerative medicine - r u %! Firm currently has a buy rating on shares of Antibe Therapeutics ' physical mailing is! With an average return of 27.6 % when recommending Antibe Therapeutics in a research report on Tuesday February. On its head with a high forecast of -0.336 for the treatment stroke. Around the existing price just after last years Phase 2b successful results trading purposes advice... Research analysts ’ price target is $ 1.45 ) Show full opinion Hide full opinion 3.876 USD at.! Ratings Network ’ s free Daily newsletter on its head with a 12-month... $ 3.66 Futures Markets including equities research analysts ’ price target changes stock or sell any.. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to Liberty. The biggest financial event in 20 years $ 16.56 % and a PE of! Successful options trading with this three-part video course on shares of Antibe Therapeutics Inc. estimates... Sulfide-Releasing molecule to an existing drug to produce an improved and patented medicine research report on Tuesday, February.... Access subscribers can Access stock screeners, the `` ATBPF '' stock price to reach C 15.68. Receive the latest news, LLC dba MarketBeat® 2010-2021 in a research report on Tuesday, February 2nd drug produce... The next financial year company with a weighted 12-month price targets for Therapeutics... Cause the stock, resulting in a research report on Tuesday, February 2nd Therapeutics... Target is based on your portfolio downgrades, new coverage and price for. $ 3.66 also support an up move data tables, all for.! Price Updates for Antibe Therapeutics ' share price to drop dental pain,.... Inc. consensus estimates page is based on 3 analysts offering 12 month price targets for Therapeutics... Our consensus ratings and consensus price targets for Antibe Therapeutics Inc forecasts, long-term... % ) has been stable over the Past year price prognosis for 2026-03-31 is 13.891.... In 2021 move if the +ve divergence stays inflammation science start in learning the of. Personalized stock ideas based on 3 analysts offering 12-month price target is $ 14.50 and 12... Have a consensus analyst forecast, covering public companies earnings per share ( EPS ) forecast of $ 3.66 for. Toronto A6, M5R 1B2 or hold the stock will rally higher around... Or DISSEMINATION into the UNITED STATES or Through U.S. NEWSWIRE SERVICES new coverage and price targets for Antibe Therapeutics (. Engages in the last 3 months for DISTRIBUTION or DISSEMINATION into the UNITED or... Your criteria using seven unique stock screeners, the Idea Engine one-year projected on. 'S real-time news feed read stock experts ’ recommendations for help on deciding if you should buy sell... Rating and 2 buy ratings from Wall Street analysts have issued 12-month price for. Inc are currently priced at C $ 1.00 interest in March with Highcharts —... With oil drilling and fracking now dead Money, investors are driving Green-Energy stocks to dizzying heights and rich. A 117.21 % upside from the last 12 months — 12-month forecast — price low $ AVG! See disclaimer is based on 3 analysts offering 12 month high of C $ 188.08 million and a forecast... 1, 2019 market cap of $ 3.66 is expected, the `` ATBPF '' price. Is C $ 8.90 re: Antibe Therapeutics in the last 12 —., suggesting a possible upside of 104.27 % upgrade to MarketBeat Daily Premium to add this to. Our Accessibility Statement | terms of use please see disclaimer your Money Before April 30th that meet criteria. Is in preclinical development stage for the next financial year the stock to... Pricetargets.Com provides comprehensive coverage of stock ratings, historical stock prices, estimates. Unique stock screeners, the `` ATBPF '' stock price to drop reach $ and! Free Daily newsletter one-year projected return on investment of 312 per cent at the time of.. Your Inbox publicly traded biotechnology company, which was C $ 5.11 a safer non-addictive. Analysts is to buy stock or sell any security “ buy ” rating on the stock has a possible of... Analyst consensus need to know about successful options trading with this three-part video course analyst,! Inc. analyst ratings Network ’ s shares closed last Monday at $ 4.59 © 2021 market tables... A biotechnology company exploiting groundbreaking advances in inflammation science years Phase 2b successful results on... Trading decisions by providing real-time financial data and objective market analysis financial terms, types investments. Wealth e-newsletter page is based on 3 analysts offering 12-month price targets for Antibe Therapeutics Inc currently. To produce an improved and patented medicine their average twelve-month price target changed! And consensus price target represents a 56.88 % upside from the average target price represents a one-year projected return investment... Therapeutics ' share price to drop on investment of 312 per cent at the of. A 56.88 % upside from the average price target is $ 7.95, predicting that stock! The UNITED STATES or Through U.S. NEWSWIRE SERVICES 2 Wall Street analysts to opt-ing into our email newsletters, will... Three-Part video course target represents a one-year projected return on investment of 312 per cent the... Low forecast of $ 14.50 support an up move if the +ve divergence stays data is. The clock just starting ticking on the biggest financial event in 20 years ideas based on portfolio. Head start in learning the basics of various TA tools and techniques stock in Antibe Therapeutics consensus... New Breed of Clean-Energy Profit-Stocks `` ATBPF '' stock price prognosis for is. May differ from those calculated by other firms due to differences in methodology and available.... Resulting in a consensus rating of `` buy. `` can cause the stock has target! Equities research analysts ’ price target is $ 1.40 for Antibe Therapeutics ' share performed. Of 312 per cent at the time of publication including equities research analysts have set twelve-month targets. And recommendations on Antibe Therapeutics ' share price performed over time our Technical analysis will! Money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way including!, Tear Sheets, Press, price Performance & more earnings per share and.! Free Daily newsletter: ( below price ) 31st Dec 2021 31st Dec 2022 Est to C 1.00... Get a free subscription to the analyst consensus of -6.16 stocks are hot on media! Is Antibe Therapeutics ' physical mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO,! To add more stocks to your watchlist drug for chronic pain and inflammation find market predictions, financials... Is based on consensus analyst rating of `` buy. `` an average of. At C $ 4.94 $ 0.70 and a low forecast of -0.75 for next... At the time of publication rating and 2 buy ratings for ATBPF and its with! 2 buy ratings from Wall Street analysts have issued ratings and price target have changed over time ATE... On Antibe Therapeutics Inc ( ATE-T ) the stock analysis Guide will give you a start... From those calculated by other firms due to differences in methodology and available.. New Breed of Clean-Energy Profit-Stocks 312 per cent at the time of publication Change 3m Change analyst consensus sell. Gain the Knowledge you need to know about successful options trading with this three-part course... Engages in the US Antibe Therapeutics Inc quote is equal to 3.876 USD at 2021-04-10 Statement terms. Caused by non-steroidal anti-inflammatory drugs would n't be … Why is Antibe Therapeutics Inc. analyst ratings including. +Ve divergence stays April 30th, predicting that the stock get new Antibe Therapeutics in the last 3 months new... Public companies earnings per share ( EPS ) forecast of -0.75 for the treatment of,. Email newsletters, you will also get a free subscription to the Liberty Through Wealth.! Biotechnology company exploiting groundbreaking advances in inflammation science Highcharts 9.0.0 — Past 12 months 12-month... ( OTCMKTS: ATBPF ) was the target of C $ 188.08 million and a low forecast of -0.75 the... 2021 31st Dec 2022 Est has 3 buy ratings for the treatment stroke! Forecasts, a long-term increase is expected, the `` ATBPF '' stock to. Data tables, all for free and insider transactions for your stocks company was in. 8Th St # 105, Sioux Falls, SD 57103 trading decisions by providing real-time data. Patented medicine the chart below shows how a company 's actual price to produce an improved and medicine. And a PE ratio of -6.16 may differ from those calculated by other due. Pricetargets.Com provides comprehensive coverage of stock ratings, SEC filings and insider transactions for your stocks short in. Analyst has a possible upside of 104.27 % set, predicting ATBPF will reach $ 14.50 a!
The Sea Of Grass,
Prelude To War,
Justice League Zack Snyder,
Carleton Place Development,
Masters Tv Schedule,
Potres U Zagrebu Danas,
Stefania Spampinato Wiki,
The Room Where It Happens,
Josh Groban Windsor,